Moxonidine: a review of its use in essential hypertension.

@article{Fenton2006MoxonidineAR,
  title={Moxonidine: a review of its use in essential hypertension.},
  author={C. Fenton and G. Keating and K. Lyseng-Williamson},
  journal={Drugs},
  year={2006},
  volume={66},
  pages={477-496}
}
Moxonidine (Physiotens®, Moxon®, Cynt®) is an orally administered imidazoline compound with selective agonist activity at imidazoline I 1 receptors and only minor activity at α 2 -adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with mild to moderate hypertension, moxonidine reduces blood pressure (BP) as effectively as most first-line antihypertensives when used as monotherapy and is also an… Expand
Centrally Acting Antihypertensive Agents: An Update
  • D. Sica
  • Medicine
  • Journal of clinical hypertension
  • 2007
Centrally Acting Antihypertensive Agents in the Treatment of Hypertension
Biphasic Dose-dependent Modulation of Cardiac Parasympathetic Activity by Moxonidine, an Imidazoline I1-receptor Agonist
  • M. Turcani
  • Chemistry, Medicine
  • Journal of cardiovascular pharmacology
  • 2008
Imidazoline I2 receptors: target for new analgesics?
...
1
2
3
4
...

References

SHOWING 1-10 OF 44 REFERENCES
Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes.
...
1
2
3
4
5
...